We commemorate the 1926 publication by Finnish physician, Eric von Willebrand, Von Willebrand, E A (1926). “Hereditär pseudohemofili”. Finska Läkaresällskapets Handlingar (in Swedish). 68: 87–112. Dr. von Willebrand’s title, “Hereditary Pseudohemophilia,” was updated to our current name, von Willebrand disease, in the late 1930s, and the responsible protein was named von Willebrand factor in 1971. Our July 2026 QQ addresses a few of the current VWD therapeutics by asking, “What VWD therapeutic is NOT a replacement factor?” Please select from Desmopressin, Humate P, Vonvendi, or Wilate, and, if you are so led, place your comments in the space below this entry. (Our June 25, 2026, post, “A New Era in VWD Rx” describes current VWD Rx research, but will not help you answer our July QQ!)
For more VWD information, please navigate to “A Coag Conversation, 100 Years of VWD and Upcoming Advances, Part 1: History and Clinical Descriptions,” featuring Robert Sidonio, MD, MSc, Medical Director, Clinical Research Office, Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, and Professor of Pediatrics, Emory University School of Medicine. Then turn to Dr. Sidonio’s “Coag Conversation Part 2: VWD Subgroups and Laboratory Testing,” posted 6-25-26. Finally, Coag Conversation Part 3, “Advanced Assays and VWD Management,” will appear in mid-July. You may choose to await Part 3, which will provide the answer to the July 2026 QQ.
No comments here.